← Back to Search

Acute Intermittent Hypoxia for Lou Gehrig's Disease (AIH in ALS Trial)

N/A

Waitlist Available

Led By Barbara K Smith, PT, PhD

Research Sponsored by University of Florida

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 hours

Awards & highlights

AIH in ALS Trial Summary

This trial will test the effects of a single session of interrupted breathing on respiratory and non-respiratory motor function in patients with ALS and healthy controls.

Eligible Conditions

Lou Gehrig's Disease
Neuromuscular Disease

AIH in ALS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximal Respiratory Pressures

Maximal Voluntary Grip Force

Secondary outcome measures

Minute Ventilation

Surface electromyography (EMG)

Ventilatory Drive

AIH in ALS Trial Design

2Treatment groups

Experimental Treatment

Group I: Healthy Control GroupExperimental Treatment2 Interventions

Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.

Group II: ALS GroupExperimental Treatment2 Interventions

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor

1,340 Previous Clinical Trials

715,676 Total Patients Enrolled

Barbara K Smith, PT, PhDPrincipal InvestigatorUniversity of Florida

3 Previous Clinical Trials

44 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are persons of age 20 and older being enrolled in this experiment?

"The accepted age ranges for this trial are between 21 and 75, as indicated by the inclusion criteria."

Answered by AI

Am I eligible to participate in this clinical investigation?

"Applicants to this medical trial must have Oppenheim disease and be between 21 and 75 years old. Approximately 56 patients are needed for the study."

Answered by AI

How many participants is the trial recruiting?

"Affirmative. Clinicaltrials.gov has records of this clinical trial, which was opened on October 1st 2018, currently seeking participants. In total, 56 individuals are required from 2 different medical sites."

Answered by AI

Are there available places for participants in this research project?

"According to the clinicaltrials.gov website, this clinical trial is actively recruiting members for participation. Initially posted on October 1st 2018 and last updated July 25th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease

2018. "Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03645031.